June 11, 2026
A Phase 2 study shows canine olfaction combined with Bayesian modeling can detect multiple cancers from breath samples with 91% accuracy.
June 1, 2026
mRNA neoantigen vaccine plus pembrolizumab shows a durable five-year survival benefit in high-risk melanoma, a pivotal proof-of-concept.
The FIGHT-302 trial shows pemigatinib improves progression-free survival in first-line FGFR2+ cholangiocarcinoma, establishing a targeted option.
May 31, 2026
A meta-analysis confirms low-dose tamoxifen halves breast cancer risk in postmenopausal women, boosting chemo-prevention accessibility.
Sacituzumab govitecan shows promise in neoadjuvant MIBC for cisplatin-ineligible patients, with potential for bladder-sparing strategies.
May 29, 2026
Adding intravesical BCG to chemo-immunotherapy for MIBC yields a compelling 68% pathological complete response rate, boosting prior results.
April 27, 2026
LEAP-010: Adding lenvatinib to pembrolizumab improved response in H&N cancer but failed to extend survival, highlighting a key paradox.
April 9, 2026
A clinical trial found a liberalized diet increases major infection risk in high-risk cancer patients vs. a neutropenic diet, with no nutritional benefits.
February 23, 2026
Atezolizumab added to bevacizumab and chemotherapy fails to improve survival in recurrent ovarian cancer in the phase 3 AGO-OV-229 trial.
February 12, 2026
Experts redefine trial design for biochemically recurrent prostate cancer, emphasizing PSMA PET nuances, de-escalation, and novel endpoints.
December 11, 2025
Experts establish consensus endpoints for bladder-sparing trials in MIBC, focusing on clinical complete response and robust event-free survival.
December 9, 2025
Pirtobrutinib shows promise as a new upfront treatment for CLL in two Phase 3 trials, demonstrating superiority and a strong safety profile.
December 7, 2025
A new staging system for AL Amyloidosis adds longitudinal strain to identify ultra-high-risk Stage 3C patients, reshaping modern prognosis.
November 24, 2025
The PACIFIC-2 trial failed to improve survival by adding durvalumab simultaneously with chemoradiation in stage III NSCLC. What's next?
November 20, 2025
Childhood cancer survivors over 50 face a 3x higher mortality risk, driven by secondary cancers and chronic conditions from past treatments.
November 13, 2025
5-year Cartitude-1 data shows one-third of RRMM patients remain progression-free after cilta-cel, sparking debate on a potential cure.
October 27, 2025
The Phase III TRILINX trial failed, showing the addition of Xevinapant to chemoradiation worsened outcomes in head and neck cancer.
October 9, 2025
Adolescent and young adult (AYA) cancer survivors face significant, long-term income loss, with some groups never fully recovering financially.
